Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: A cluster randomized trial by Sandvik, Reidun Karin et al.
ORIGINAL ARTICLE
Impact of a stepwise protocol for treating pain on pain
intensity in nursing home patients with dementia: A cluster
randomized trial
R.K. Sandvik1,2,3, G. Selbaek3,4,5, R. Seifert6, D. Aarsland7,8, C. Ballard8,9, A. Corbett9, B.S. Husebo1,8
1 Department of Global Public Health and Primary Care, Centre for Elderly- and Nursing Home Medicine, University of Bergen, Norway
2 Institute for Nursing Subjects, Bergen University College, Norway
3 Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway
4 Ageing and Health, Norwegian Centre for Research, Education and Service Development, Vestfold Hospital Trust, Tønsberg, Norway
5 Akershus University Hospital, Lørenskog, Norway
6 Heart Department, Haukeland University Hospital, Bergen, Norway
7 Department of Neurobiology, Care Sciences and Society, KI-Alzheimer Disease Research Center, Karolinska Institute (KI), Solna, Sweden
8 Center for Age-Related Medicine, Stavanger University Hospital, Norway
9 The Wolfson Wing & Hodgkin Building Guys Campus, Kings College, London, UK
Correspondence
Reidun K. Sandvik
E-mail: reidun.sandvik@igs.uib.no
Funding sources
This study was funded by the Norwegian
Research Council (protocol code 189439) and
the University of Bergen (09/1568). We
gratefully thank the Centre for Old Age
Psychiatric Research, Innlandet Hospital Trust
in Ottestad for granting R.K.S. B.S.H. and A.C.
acknowledge support from the COST
program (European Cooperation in the Field
of Scientiﬁc and Technical Research) for
COST-ACTION TD-1005: Assessment of Pain in
Patients with Mental Impairment, especially
Dementia.
Conﬂicts of interest
C. Ballard declares associations with the
following companies: Acadia, Bristol-Myers,
Squibb, Esai, Janssen, Lundbeck, Novartis
and Shire. D. Aarsland declares associations
with the following companies: DiaGenic, GE
Healthcare, GlaxoSmithKline, Lundbeck,
Merck Serono and Novartis. A. Corbett
declares associations with Novartis,
Lundbeck, Bial and Acadia. Other authors
have no disclosures to report.
Accepted for publication
6 April 2014
doi:10.1002/ejp.523
Abstract
Background: Pain is frequent and distressing in people with dementia,
but no randomized controlled trials have evaluated the effect of analgesic
treatment on pain intensity as a key outcome.
Methods: Three hundred fifty-two people with dementia and significant
agitation from 60 nursing home units were included in this study. These
units, representing 18 nursing homes in western Norway, were
randomized to a stepwise protocol of treating pain (SPTP) or usual care.
The SPTP group received acetaminophen, morphine, buprenorphine
transdermal patch and pregabalin for 8 weeks, with a 4-week washout
period. Medications were governed by the SPTP and each participant’s
existing prescriptions. We obtained pain intensity scores from 327 patients
(intervention n = 164, control n = 163) at five time points assessed by the
primary outcome measure, Mobilization-Observation-Behaviour-
Intensity-Dementia-2 (MOBID-2) Pain Scale. The secondary outcome was
activities of daily living (ADL). We used a linear intercept mixed model in
a two-way repeated measures configuration to assess change over time
and between groups.
Results: The SPTP conferred significant benefit in MOBID-2 scores
compared with the control group [average treatment effect (ATE) −1.388;
p < 0.001] at week 8, and MOBID-2 scores worsened during the washout
period (ATE = −0.701; p = 0.022). Examining different analgesic
treatments, benefit was conferred to patients receiving acetaminophen
compared with the controls at week 2 (ATE = −0.663; p = 0.010),
continuing to increase until week 8 (ATE = −1.297; p < 0.001). Although
there were no overall improvements in ADL, an increase was seen in the
group receiving acetaminophen (ATE = +1.0; p = 0.022).
Conclusion: Pain medication significantly improved pain in the
intervention group, with indications that acetaminophen also improved
ADL function.
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®.
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1. Introduction
Dementia affects approximately 10 million people in
Europe, and this is expected to double every 20 years
as the population ages (Kalaria et al., 2008). One-third
of people with dementia reside in nursing homes
(NHs). In addition to the distress experienced by these
individuals as a result of their condition, many also
experience pain (Achterberg et al., 2007). The precise
prevalence of pain is unclear, but estimates indicate
that up to 80% of NH patients are in acute or chronic
pain (Husebo et al., 2008; Achterberg et al., 2010,
2013). The majority experience persistent pain lasting
6 months or longer (Pickering et al., 2006). The most
common types of pain are musculoskeletal, such as
arthritis, or neuropathic pain as result of diabetes or
stroke (Scherder and Plooij, 2012). Despite the high
prevalence of pain in these individuals, assessment is
difficult due to the loss of cognitive and communica-
tive abilities.
Pain is distressing for the individual who experi-
ences it and often correlates with key symptoms,
ranging from problems with coordination and
memory to changes in personality and behaviour. This
can also lead to an increased risk of falls (Deandrea
et al., 2010; Huang et al., 2012), behavioural and psy-
chological symptoms of dementia (BPSD) such as agi-
tation and aggression (Hurley et al., 1992; Lin et al.,
2011; Ahn and Horgas, 2013; Husebo et al., 2013),
and depression (Cohen-Mansfield and Taylor, 1998).
In addition, undertreated pain affects social interac-
tion, provokes sleep disturbances and reduces quality
of life (Giron et al., 2002; Cipher and Clifford, 2004;
Cordner et al., 2010). Furthermore, people experienc-
ing BPSD due to pain may be inappropriately pre-
scribed anti-psychotic medication, which can be
harmful, rather than analgesia (Corbett et al.,
2012a,b).
A limitation in the existing literature is the lack of
large randomized controlled trial (RCT) studies with
pain intensity as the main outcome (Corbett et al.,
2012a,b). To date, no large-scale pain intervention
studies have focused upon improvement of pain
intensity as a key outcome (Lorenz et al., 2008). Most
studies, including four RCTs, have utilized measures of
BPSD, mood or activities of daily living (ADL) as proxy
measures of pain (Manfredi et al., 2003; Buffum et al.,
2004; Chibnall et al., 2005; Kovach et al., 2006). All
RCTs were performed in the NH setting and with aged
patients investigating the effect of pain medication on
agitation. However, none of these trials included a
measure of pain or a systematic pain management
protocol.
The absence of data regarding the impact of pain
intensity is, in part, due to the challenge of accurately
identifying pain robustly. We recently developed and
tested the Mobilization-Observation-Behaviour-
Intensity-Dementia-2 (MOBID-2) Pain Scale for use in
NH patients with dementia (Husebo et al., 2010). This
article reports secondary analyses of an 8-week RCT
with follow-up assessment after a 4-week washout
period to investigate the effect of pain treatment on
pain intensity in NH patients with dementia, assessed
by the MOBID-2 Pain Scale.
2. Methods
The trial is registered at ClinicalTrials.gov (number
NCT01021696) and at the Norwegian Medicines Agency
(EudraCT nr: 2008-007490-20). Ethical approval was
obtained in accordance with local law, by the Regional Com-
mittee for Medical Ethics, Western Norway (REK-Vest
248.08) and by the authorized Institutional Review Board of
each participating institution.
2.1 Study design
This study was an 8-week RCT comparing the effect of the
stepwise protocol of treating pain (SPTP) intervention with
control in people with dementia living in Norwegian NHs.
The trial included a 4-week washout period with additional
follow-up at 12 weeks. The recruitment strategy of 18 NHs,
patient samples and full study design has been described in
our previous publication (Husebo et al., 2011).
What’s already known about this topic?
• Many people with dementia experience pain
regularly, but are not able to communicate this to
their carers or physicians due to the limited self-
report capacity inherent in the symptomatology
of dementia.
• Few studies have investigated the direct effect of
pain treatment on pain intensity in patients suf-
fering from dementia, with previous studies
using proxy measures of behavioural symptoms.
What does this study add?
• A stepwise protocol to treat pain in nursing
home residents with moderate to severe demen-
tia significantly reduced pain intensity.
• Pain treatment by acetaminophen improved
activities of daily living.
• There is an urgent need for a standardized
approach to assessment and treatment of pain for
nursing home residents with dementia.
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2.2 Eligibility criteria
Participants included in this study were people aged 65 years
and older residing in a NH for at least 4 weeks. Inclusion
criteria were a diagnosis of Alzheimer’s disease or other
dementias according to Diagnostic and Statistical Manual of
Mental Disorders, a Functional Assessment Staging score >4
(Reisberg et al., 1982) and clinically relevant behavioural
disturbances defined as Cohen Mansfield Agitation Inven-
tory score ≥39 (i.e., at least 1-week history of clinically sig-
nificant agitation) (Cohen-Mansfield et al., 1989; Finkel
et al., 1992). Only patients with moderate or severe demen-
tia, defined as a score of <20 on the Mini-Mental State
Examination scale (MMSE) (range 0–30), were included
(Folstein et al., 1975). Residents were included independent
of painful diagnoses, presumed pain or ongoing pain treat-
ment. Residents were excluded if they had an expected sur-
vival of less than 6 months, severe psychosis or allergy to any
of the study drugs. Written informed consent included a
description of the study design, benefit and possible side
effects of the trial. We took into consideration that even
individuals with mild cognitive impairment might have
impaired capacity to consent to research (Warner and
Nomani, 2008; Ayalon, 2009) and obtained informed
consent from all patients and all surrogates/caregivers or the
authorized legal representatives. Caregivers also gave
consent to participate as informants.
2.3 Intervention
The SPTP followed the latest recommendations of the Ameri-
can Geriatric Society (AGS) Panel for pharmacological man-
agement of persistent pain in older adults (AGS Panel on
Persistent Pain in Older Persons, 2009) and is described in
our previous publication (Husebo et al., 2011). All patients
assigned to the treatment group were investigated individu-
ally by the responsible team, which consisted of the NH
physician, the patient’s primary caregiver, a pain therapist
(B.S.H.) and a research assistant (R.K.S.). After a thorough
discussion, the team agreed on the most appropriate pain
medication and dosage according to the standardized SPTP
protocol. Depending upon their existing prescribed pain
treatment, patients received titrated analgesia in a stepped
approach. Patients previously receiving no or low dose of
acetaminophen received acetaminophen orally (3 g/day)
(step 1). If they already had a prescription of acetaminophen,
they were adjusted to either extended release morphine
orally (10 or 20 mg/day) (step 2) or buprenorphine trans-
dermal patch (5 μg or 10 μg/h for 7 days) (step 3). If patients
were already receiving step 3 medications and had neuro-
pathic pain, they received pregabalin orally (25, 50 or 75 mg/
day) (step 4), using a fixed dose regime throughout the
8-week treatment period. Most cases at steps 2–4 received
combination therapy with different analgesics. Patients with
swallowing difficulties started at step 3. Medication was
offered at breakfast, lunch and dinner (approximately 08:00,
13:00 and 18:00 h), respectively. In patients who were not
able to tolerate this treatment, the dosage was reduced or the
patient was withdrawn from the study and treated as clini-
cally appropriate. The treating physicians were instructed to
keep prescriptions and doses of analgesics unchanged in the
control group.
2.4 Outcome measures
Outcome measures were completed at baseline, 2, 4, 8 and
12 weeks. The MOBID-2 Pain Scale was used to assess pain
intensity in the participants. MOBID-2 is a two-part staff-
administered observational pain behaviour instrument,
developed and tested in NH patients with advanced demen-
tia (Husebo et al., 2010). Assessment of pain intensity is
based upon the patient’s immediate pain behaviour such as
vocalization, facial expression and use of defensive body
positions. MOBID-2 part 1 assesses pain related to the mus-
culoskeletal system in connection with standardized, guided
movements during morning care (five items). MOBID-2 part
2 assesses pain that might originate from internal organs,
head and skin and is monitored over time (five items). After
registration of pain behaviour, observations are inferred to
pain intensity using a 10-point numerical rating scale (NRS).
Caregivers are encouraged to judge whether the observed
behaviour is related to pain or to dementia and psychiatric
disorders. Finally, an independent overall pain intensity
score is completed, again using a NRS. Previous studies on
the psychometric properties of MOBID and MOBID-2 pain
scale have showed that the inter- and intra-rater and test–
retest reliability of the scale is very good to excellent, with
Intra Class Correlations ranging from 0.80 to 0.94 and from
0.60 to 0.94, respectively (Husebo et al., 2007, 2009, 2010).
Internal consistency was highly satisfactory with Cronbach’s
α ranging from 0.82 to 0.84. Face, construct and concurrent
validity was good and it has shown good feasibility in clinical
practice (Husebo et al., 2007, 2009). Indications were pro-
vided that MOBID-2 is responsive to a decrease in pain
intensity after pain treatment (Husebo et al., 2014).
An additional outcome measure was physical function
assessed with the Barthel ADL index (range 0–20), in which
higher values indicate higher levels of activities of daily func-
tioning and independence (Mahoney and Barthel, 1965).
Safety and tolerability were monitored at each assessment,
and all adverse events and vital signs were recorded.
2.5 Randomization and blinding
Randomization was executed using Stata version 8 (Stata-
Corp LP, College Station, TX, USA). To eliminate selection
bias at institution level, we defined a cluster as a single
independent NH unit (with no crossover of staff), and ran-
domized these units. Thus, patients in each cluster were
randomly assigned to receive SPTP in the intervention group
or continue with treatment as usual (control group), using a
computer-generated list of random numbers for allocation of
the clusters by the study statistician. During enrolment, two
trained research assistants interviewed the patients’ primary
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caregivers. The outcome measures and drug prescriptions
were reviewed by a consultant for old age psychiatry (D.A.),
an anaesthetist and pain therapist (B.S.H.), one of the
research assistants (R.S.) and a senior member of staff,
usually a general practitioner from the NH after completion
of the enrolment process and prior to randomization.
Researchers and nurses with responsibility for carrying out
the intervention did not participate in data collection.
Research assistants and staff members who collected the data
were blinded to group allocation and type of intervention
during the study period. The staff were instructed not to
discuss management procedures.
2.6 Data analysis
The mean, standard deviation (SD) and range were calcu-
lated for participant demographics. We described the groups
at baseline with two-sample independent t-tests for normally
distributed continuous variables, chi-square test for categori-
cal variables and Mann–Whitney test for continuous vari-
ables with non-normal distribution. Differences in mean and
standard error (SE) of the mean MOBID-2 Pain Scale and
ADL scores over time between treatment groups were esti-
mated with linear random intercept quantile mixed-effect
models. Mixed model regression modelled with linear
random intercept permits multiple measurements per person
over time, irregular intervals between measurements and
allows for incomplete data on assumption that data are
missing at random (Verbeke and Molenberghs, 2000). We
included the NH units as a nestling level in our analysis.
Statistical analyses were conducted with IBM SPSS Statistics
for Windows version 21.0 (IBM Corp, Armonk, NY, USA)
and R version 3.0.0 (The R Foundation for Statistical Com-
puting, Vienna, Austria) and package nlme-3.1-109.
3. Results
3.1 Cohort characteristics
Four hundred twenty eligible patients were identified,
of whom 352 were included and cluster randomized to
control (n = 177, cluster n = 27) or intervention
groups (n = 175, cluster n = 33). In total, 327 partici-
pants had a MOBID-2 pain score at baseline and were
included in this stepwise protocol of treating pain
analyses (control n = 163, intervention n = 164).
Dropout rate was equally distributed between groups.
The detailed flow of participants through this study is
summarized in Fig. 1. Demographic data for the
cohort are presented in Table 1. No differences were
found between the groups at baseline.
Pain diagnoses and intensity were distributed
equally between control and intervention groups at
baseline. Over 70% of participants had one or more
diagnoses of pain (Table 1). Inferred pain intensity
greater than zero was observed in over 80% of the
patients (n = 282), and intensity of 3 or higher was
seen in over 60% (n = 203). MOBID-2 part 1 assess-
ment indicated that the majority of pain resulted from
guided movements of the legs and from turning over
in bed. MOBID-2 part 2 showed the most frequently
affected sites were the pelvis/genital organs and skin
(Table 2). We found no differences in pain intensity
between groups with different levels of dementia
assessed by MMSE (p = 0.196). Participants who were
assumed to have neuropathic pain and were treated
with pregabalin had significantly higher pain scores
than controls and the other treatment groups at base-
line (MOBID-2 pain score 6.1; p = 0.001). Pain inten-
sity did not differ between the other groups at
baseline: control group (MOBID-2 pain score 3.65),
acetaminophen group (mean 3.53; p = 0.674) and
morphine group (extended release morphine and
buprenorphine) (mean 3.97; p = 0.469).
3.2 SPTP treatment allocation
In the intervention group, 62.8% of the patients
(n = 103) started administration of acetaminophen
(step 1) (i.e., acetaminophen 3 g/day), and 5.5%
(n = 9) had an existing prescription of lower dose acet-
aminophen increased to a higher dosage. Thus, 112
patients received acetaminophen only. Three patients
received step 2, all three had acetaminophen as well
(two started with extended release morphine, and in
one participant the primary prescription was
adjusted). Step 3, the buprenorphine transdermal
patch, was administered to 29 patients (17.7%), and
the buprenorphine dosage was increased in an addi-
tional eight participants. In total, 37 participants were
treated with buprenorphine transdermal patch, of
whom 9 received the patch alone, with no other medi-
cation, due to swallowing issues. Twelve participants
were treated with step 4, pregabalin, all of whom also
received acetaminophen and the buprenorphine
patch. All other patients (n = 28) had a combination of
acetaminophen and buprenorphine.
3.3 Outcome measures
Analysis of pain intensity outcomes showed a signifi-
cant improvement in the treatment group compared
to controls in weeks 2 [average treatment effect (ATE)
−0.703; SE 0.24; p = 0.004] and 8 (ATE = −1.393; SE
0.3; p < 0.001) (Table 2). This improvement was seen
in MOBID-2 overall pain intensity (Fig. 2) in addition
to specific items assessing musculoskeletal pain
(Fig. 3) and pain related to internal organs, head and
R.K. Sandvik et al. Pain treatment in dementia
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®
Eur J Pain 18 (2014) 1490–1500 1493
skin (Fig. 4). A sub-analysis of the participants who
had a score of 3 or greater on the MOBID-2 Pain Scale
at baseline also showed significant benefit in the treat-
ment group compared with control (ATE = −1.739;
p < 0.001) in week 8, with an average difference in
pain reduction of 50% from baseline to week 8 in the
treatment group.
An analysis of the efficacy of different treatment
approaches within the treatment group is presented in
Fig. 5 and shows that participants treated with acet-
aminophen had significant improvement of pain at all
time points, at week 2, 4 and 8, respectively
(ATE = −0.67, p = 0.010; ATE = −0.92, p < 0.001;
ATE = −1.30, p < 0.001). Patients treated with
extended release morphine or buprenorphine trans-
dermal patch also showed a significant decrease in
MOBID-2 total scores, but not before week 8
(ATE = −1.14; p = 0.008). Patients treated with pre-
gabalin had a clinically and statistically significant
effect after 4 weeks (ATE = −1.8; p = 0.016) and
showed a 61.7% reduction in pain from baseline to
week 8 (ATE = −3.53; p < 0.001) compared with the
control group. All participants treated with analgesia
experienced worsening of pain following discontinu-
ation of treatment during the washout period (acet-
aminophen: ATE = −0.76, p = 0.004; morphine or
buprenorphine: ATE = −0.223, p = 0.075 pregabalin:
ATE = −1.438, p = 0.075) (Fig. 5).
As previously reported (Husebo et al., 2011), no
significant differences were seen in ADL between
intervention and control groups at week 8 (p = 0.443).
However, a sub-analysis of the acetaminophen group
demonstrated improved ADL from baseline in the
intervention group (ATE = +1.00; p = 0.022) at week 8
compared with the control group (Fig. 6). Entering NH
unit as a nestling level did not alter our findings.
3.4 Adverse events
Adverse events related to pain treatment interventions
were registered for six patients (nausea n = 1, rash
from patch n = 1, reduced appetite n = 2, somnolence/
drowsiness n = 2). Most patients had acetaminophen
(n = 120), but few left the study due to side effects
(n = 2). Twice as many left from the opioid group
(n = 4), although this group counted only 33% com-
Assessed for eligibility (n = 420)
Excluded  (n = 93)
♦ Not meeting inclusion criteria (n = 47)
♦ Declined to participate (n = 4)
♦ No pain intensity score (n = 25)
MOBID-2 pain scale total score (n = 152)
Lost to follow-up  (n = 4)
♦ Died (n = 2)
♦ Moved (n = 2) 
MOBID-2 pain scale total score (n = 156)
Lost to follow-up  (n = 3)
♦ Died (n = 3) 
Allocated to care as usual (n = 163) 
MOBID-2 pain scale total score (n = 143)
Lost to follow-up  (n = 1)
♦ Moved (n = 1) 
 
 
 
Allocated to stepwise protocol for treatment
of pain (n = 164)  
Allocation
Randomized (n = 327)
Enrolment
MOBID-2 pain scale total score (n = 144)
Lost to follow-up  (n = 19)
♦ Withdrew consent (n = 3)
♦ Died (n = 5)
♦ Acute psychiatric illness (n = 3)
♦ Drowsiness (n = 2)
♦ Nausea (n = 1)
♦ Moved (n = 1)
♦ Skin allergic reaction (n = 1)
♦ Reduced condition (n = 1)
♦ Administration (n = 2)  
 
MOBID-2 pain scale total score (159)
Lost to follow-up  (n = 5)
♦ Died (n = 3)
♦Reduced condition (n = 1) 
Week 2
MOBID-2 pain scale total score (n = 137)
Lost to follow-up  (n =  6)
♦ Died (n = 3)
♦ Administration (n = 3)
Week 8
Week 4
Figure 1 Flow chart showing patients ﬂow
through the 12-week study period including
control and intervention groups.
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pared with the acetaminophen group. Pregabalin was
given to 12 patients and 2 left the study. Fourteen
deaths occurred during the 8-week study, of which six
were participants in the intervention group.
4. Discussion
Pain is a clinically significant issue in dementia and is
known to be related to the development of challeng-
ing symptoms such as BPSD and to have a significant
impact on the quality of life and well-being. This
article reports the first study to specifically measure
the effect of pain treatment on the intensity of pain
in people with dementia living in NH. This secondary
analysis has shown that a stepwise approach to treat-
ing pain, which is tailored to the individual and
adapted according to the patients’ ongoing pain
medication, significantly improved overall pain
intensity in residents with moderate and severe
dementia as measured by the MOBID-2 Pain Scale.
Pain intensity was reduced by 45% in the interven-
tion group after 8 weeks of treatment. All treatments
resulted in benefit at the 8-week time point, with
pregabalin also conferring effective pain relief by
week 4, and acetaminophen providing benefit after 2
weeks. Importantly, all participants receiving analge-
sia experienced a significant worsening of pain when
treatment was discontinued at the end of the trial. In
addition to the impact on pain intensity, the study
also found a significant improvement in physical
function in participants receiving acetaminophen at 8
weeks. Pain is known to influence mobility and
ability to perform daily tasks, and this is an impor-
tant outcome. Since individuals receiving acetamino-
phen within step 1 of the SPTP for the full 8 weeks
were predominantly experiencing mild or moderate
pain, this finding indicates the additional value of
analgesia for these individuals. Taken together, these
findings clearly indicate the value of prompt and
ongoing analgesic treatment in people with dementia
where it is clinically appropriate.
Clinical guidelines for older adults have been pub-
lished by the AGS panel from 1998, with regular
updates in 2002 and 2009 (AGS Panel on Persistent
Pain in Older Persons, 2009). The latest version also
includes recommendations for accurate pain assess-
ment in patients with dementia. However, guidelines
for treatment of pain in patients with dementia are still
urgently needed. We applied the recommendations
from the AGS panel guidelines and focused upon titra-
tion and combination of two or more drugs with
complementary mechanisms to attain improved pain
reduction with less hepatic and kidney toxicity and
adverse effects. Following the recommendations for
clinicians, we used a maximum safe dose (<4 g/24 h)
of acetaminophen for our patients (AGS Panel on
Persistent Pain in Older Persons, 2009).
To our knowledge, this is also the first RCT to evalu-
ate the anti-epileptic pregabalin to specifically treat
neuropathic pain in patients with dementia. Treat-
ment followed recommendations by the AGS panel,
starting on low doses (25 mg/day), increasing to
75 mg/day where necessary. Pregabalin selectively
binds to voltage-gated calcium channels in the brain
and spinal cord and has been shown to decrease the
release of excitatory neurotransmitter and reduce
calcium channel function (Dooley et al., 2000;
Fehrenbacker et al., 2003; Micheva et al., 2006). Pre-
gabalin has shown initial benefit in an RCT of painful
diabetic neuropathy (Rosenstock et al., 2004). Despite
Table 1 Demographic and clinical characteristics of the study popula-
tion. Variables reported as mean (SD), medians (SE) and proportions (%).
Characteristic
Control mean
(SD)
n = 163
Intervention
mean (SD)
n = 164 p
Agea 86.4 (6.7) 85.2 (7.0) 0.102
Women (%)b 131 (74.0) 131 (74.9) 0.856
MMSEc,d 8.9 (6.6) 7.6 (6.6) 0.065
Barthel ADL indexc,e 8.7 5.5) 7.8 (5.6) 0.148
MOBID-2 Pain Scalec,f 3.7 (2.5) 3.8 (2.7) 0.988
MOBID-2 Pain Scale ≥ 1c 4.2 (2.2) 4.5 (2.4) 0.273
MOBID-2 Pain Scale ≥ 2c 4.5 (2.1) 4.9 (2.2) 0.213
MOBID-2 Pain Scale ≥ 3c 5.3 (1.8) 5.4 (2.0) 0.830
No pain diagnoses in total (%)c 29.4 29.4 0.823
1 pain diagnoses (%) 30.8 30.3
2 pain diagnoses (%) 24.4 22.6
≥3 pain diagnoses (%) 16.0 18.1
Old fracture (%)b 27.6 27.1 0.801
Arthritis (%)b 22.4 20.0 0.600
Osteoporosis (%)b 20.5 23.9 0.477
Heart (%)b 17.9 15.5 0.561
Cancer (%)b 16.7 20.0 0.448
Neuropathy (%)b 1.9 4.5 0.196
Wound gangrene (%)b 1.3 3.9 0.150
Muscle spasm (%)b 1.3 2.6 0.406
MMSE, Mini-Mental State Examination (scores from 0 to 30); ADL, activi-
ties of daily living (scores 0–20); MOBID-2, Mobilisation-Observation-
Behaviour-Intensity-Dementia-2 Pain Scale.
at-Test for continuous variable, normally distributed.
bChi-square test for dichotomous categorical variables.
cMann–Whitney U for unequal distributed continuous variable given in
medians (SE). Variables reported as mean (SD) and median (%) if not indi-
cated otherwise.
dLower scores indicate more cognitive impairment.
eHigher scores indicate better function.
fHigher scores indicate more pain (scores ≥ 3 accepted as clinically
relevant).
R.K. Sandvik et al. Pain treatment in dementia
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®
Eur J Pain 18 (2014) 1490–1500 1495
only 12 participants receiving pregabalin, the data
indicate significant benefit. This finding is of particular
importance due to the frequency of central neuro-
pathic pain in people with dementia associated with
white matter lesions in people who have experienced
a stroke (Scherder et al., 2003; Scherder and Plooij,
2012). Studies also indicate the presence of neuro-
pathic pain in people with vascular dementia, mixed
dementia, Alzheimer’s disease and frontotemporal
dementia as a result of specific neuropathology
(Scherder et al., 2003; Rosenstock et al., 2004; Husebo
et al., 2008; Scherder and Plooij, 2012). Furthermore,
diabetes is particularly common among people with
dementia and is associated with considerable neuro-
pathic pain (Wild et al., 2004; Zilliox and Russell,
2011). Pregabalin therefore warrants further investi-
gation as an analgesic treatment option for this group.
Our dataset has revealed valuable data regarding the
specific tolerability of different pharmacological treat-
ments for pain in this patient group. The largest pro-
portion of participants in the trial who received
treatment was prescribed with acetaminophen. This
Table 2 Efﬁcacy of treating pain on different locations of pain with the sum scores of musculoskeletal pain (MOBID-2 part 1) and pain from internal organs
head and skin (MOBID-2 part 2) between control group and treatment group at baseline and in week 8 (n = 327).
Pain location
Control (n = 163) Intervention (n = 164)
Baseline mean
(SE)
Week 8 mean
(SE) Difference
Baseline mean
(SE)
Week 8 mean
(SE) Difference dfa ta pa
Hands 0.8 (0.2) 1.0 (0.1) 0.161 1.1 (0.2) 0.8 (0.2) −0.243 1183 −2.457 0.014
Arms 1.7 (0.2) 1.8 (0.2) 0.119 1.8 (0.2) 1.2 (0.2) −0.677 1180 −2.868 0.004
Legs 2.6 (0.2) 2.2 (0.2) −0.342 2.0 (0.2) 1.6 (0.2) −0.375 1174 −0.177 0.859
Turn over 1.9 (0.2) 2.0 (0.2) 0.026 2.0 (0.2) 1.3 (0.2) −0.739 1156 −2.665 0.008
Sit 1.6 (0.2) 2.0 (0.2) 0.398 2.1 (0.2) 1.2 (0.2) −0.826 1154 −4.498 <0.001
Part 1 total score 8.7 (0.8) 8.9 (0.7) 0.393 9.0 (0.8) 5.8 (0.8) −3.233 1132 −3.567 <0.001
Head, mouth, neck 1.0 (0.1) 0.9 (0.1) −0.091 1.4 (0.2) 0.8 (0.1) −0.627 1184 −2.548 0.011
Heart, lung, chest 0.8 (0.2) 0.8 (0.1) 0.049 0.8 (0.1) 0.4 (0.1) −0.426 1182 −2.675 0.008
Abdomen 0.9 (0.1) 0.7 (0.1) −0.143 1.0 (0.2) 0.4 (0.1) −0.546 1182 −1.823 0.069
Pelvis, genital organs 1.6 (0.2) 1.6 (0.2) −0.023 1.8 (0.2) 0.8 (0.2) −0.944 1182 −3.276 0.001
Skin 1.7 (0.2) 1.4 (0.2) −0.208 1.5 (0.2) 1.0 (0.2) −0.570 1184 −1.458 0.145
Part 2 total score 5.9 (0.5) 5.4 (0.4) −0.416 6.5 (0.5) 3.4 (0.4) −3.113 1177 −3.766 <0.001
Overall pain intensity 3.7 (0.2) 3.4 (0.2) −0.297 3.8 (0.2) 2.1 (0.2) −1.655 1123 −5.277 <0.001
df, degree of freedom; SE, standard error.
Part 1 = musculoskeletal pain.
Part 2 = pain related to internal organs head and skin.
aRandom-intercept model in a two-way repeated-measure conﬁguration.
Figure 2 MOBID-2 Pain Scale total score withmean and standard error of
the mean by control and treatment group over study period in total study
sample.
Figure 3 Mean and standard error of the mean in musculoskeletal pain
(MOBID-2 Pain Scale part 1) scores by control and intervention groups
over study period.
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treatment was extremely well tolerated. Only 2 of 120
patients left the study, both because patient’s relatives
withdrew consent. Acetaminophen is therefore both
effective and very well tolerated by people with
dementia, confirming the suitability of this agent as a
first-line analgesic. Forty participants received an
opioid analgesic (extended release morphine or
buprenorphine transdermal patch), of whom four
withdrew due to possible side effects (femur fracture,
drowsiness and nausea, local reaction to the transder-
mal patch, appetite and eating disturbances). This
outcome reflects the literature, which indicates that
the opioid drug class is generally well tolerated with
the most common adverse drug reactions being
arrhythmia (12.1%), pruritus (10.5%), nausea (9.2%)
and dizziness (4.6%) (Hamunen et al., 2008; Huang
and Mallet, 2013), in addition to an increased risk of
falls and hip fractures (Deandrea et al., 2010). While
buprenorphine appears to be safe in people with renal
impairment, it should be noted that due to the meta-
bolic pathway of this agent, careful monitoring is
required in people with hepatic impairment, and this
is an important consideration when prescribing to
people with dementia. The only previous RCT of an
opioid for pain in dementia reported a high 47%
dropout rate (Manfredi et al., 2003). Our study has
demonstrated efficacy and improved tolerability with
buprenorphine administered through transdermal
patches, which are already in use to treat chronic
nociceptive, neuropathic and cancer-related pain
(Pergolizzi et al., 2010). Following recommendations
by the AGS panel to keep stable blood levels, 12
patients received the buprenorphine patch only, as
they already were on a strong morphine option and
had swallowing difficulties.
The late-onset effect of buprenorphine transdermal
patch after 8 weeks was an unexpected finding. Cog-
nitive function and ADL function were stable over the
period, suggesting that reduced pain was a treatment
effect and not related to sedation. The lower tolerabil-
Figure 4 Mean and standard error of the mean in pain related to internal
organs, head and skin (MOBID-2 Pain Scale part 2) by control and inter-
vention groups over study period.
Figure 5 MOBID-2 Pain Scale total score withmean and standard error of
the mean, ordered by different analgesics (acetaminophen, extended
release morphine and buprenorphine transdermal patch and pregabalin)
and control group over study period.
Figure 6 Activity of daily living total score with mean and standard error
of the mean, in order to different analgesics (acetaminophen, extended
release morphine and buprenorphine transdermal patch and pregabalin)
and control groups over study period.
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ity of opioids in people in dementia indicates the need
for an intermediate analgesic as an alternative to esca-
lation to opioids where acetaminophen is not suffi-
cient. There are both benefits and harms associated
with the use of non-steroidal anti-inflammatory drugs
(Huang et al., 1999; Bannwarth, 2008), and a further
evaluation of this analgesic group could be of value in
informing the management of pain in people with
dementia in the future.
Withdrawal among participants receiving pregaba-
lin was relatively high in this study, with 2 of 12
participants withdrawing due to somnolence, nausea
and drowsiness. This occurred despite the lower
dosage used in the study (25 mg) compared with the
recommended daily dose of 150 mg used in younger
individuals where the safety profile is very good. This
provides the first safety data for pregabalin in this
patient group. However, our results have to be con-
trolled by a clinical trial with appropriate sample
size.
To date, the prevalence of pain in people with
dementia in NH has not been fully established. While
it was not the primary purpose of this study, baseline
data indicate that almost 60% of these individuals
were experiencing significant pain, with a pain score
of at least 3. Furthermore, almost 70% had one or
more diagnoses of pain, indicating an extensive preva-
lence of pain. The pattern of prescribing within the
SPTP also indicates that many individuals were receiv-
ing suboptimal analgesia prior to the study commenc-
ing, most likely due to undiagnosed mild or moderate
pain. These secondary findings provide further weight
to the need for more effective identification of pain in
dementia through an accurate and easily implement-
able assessment and monitoring tool. The MOBID-2
Pain Scale utilized in this study has shown excellent
reliability and sensitivity to date, and this study further
confirms its utility in research. It will now be essential
to further establish its use in clinical practice in order
to provide health-care professionals with adequate
knowledge, as well as an effective pain assessment
(Pieper et al., 2013).
This is the largest study to have investigated the
effect of pain treatment on pain intensity in people
with dementia living in NH. It has provided robust,
well-powered and clinically meaningful data that
demonstrate the efficacy of a stepped pharmacological
treatment approach in this patient group. A possible
limitation in this study may be the heterogeneous
nature of the dementia cohort as no definition was
made of the sub-types of dementia within the partici-
pants. However, due to the frequent absence of a
differential diagnosis in people with dementia in NH, it
is more meaningful to consider treatment effects in
this group since it is representative of the current
clinical situation and will provide information that can
be directly translated to guidance for practice. The data
provide robust data for the overall cohort. Efficacy
data for the individual pharmacological agents are
necessarily derived from smaller groups of participants
due to the stepped nature of the intervention. It would
therefore be a valuable next step to evaluate each of
the agents in larger cohorts to confirm the efficacy
demonstrated in this study. Further evaluation of
alternative treatment options such as anticonvulsants,
antidepressants and novel analgesics is also urgently
needed in order to establish the most effective step-
wise treatment regimen for this patient group.
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